By Josh Beckerman

Perspective Therapeutics shares declined after it presented updated interim data from an ongoing Phase 1/2a trial of cancer drug VMT-alpha-NET.

The stock was recently down 29% to $3.19 on Monday and is flat for the year to date.

Perspective reported data from the study of patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. It said the drug "continues to demonstrate durable anti-tumor activity and excellent tolerability."

Perspective said its "remarkable" safety data provides flexibility in dosing as the company advances its clinical development.

Wedbush noted favorable aspects of the results including the drug's safety profile. Oppenheimer said it anticipated the results were "likely to disappoint the Street."

Perspective also updated its cash position and cash runway. The company said its preliminary Sept. 30 cash, cash equivalents and short-term investments balance was about $174.1 million. The company expects this balance to be sufficient to fund its current planned operations and capital investments into late 2026.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 20, 2025 15:53 ET (19:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.